Cancer and coagulation
Open Access
- 8 February 2012
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 87 (S1) , S82-S87
Abstract
Thromboembolism, including both venous and arterial events, occurs commonly amongst patients with cancer. The occurrence of thromboembolism has significant consequences for cancer patients, including direct and indirect associations with mortality, morbidity, requirement for long‐term anticoagulant therapy and consumption of healthcare resources. Recent studies have resulted in a better understanding of clinical risk factors and biomarkers of cancer‐associated thrombosis, and a risk assessment model incorporating both has now been validated in multiple settings. Thromboprophylaxis with either unfractionated heparin or low‐molecular‐weight heparins (LMWHs) has been shown to be safe and effective in high‐risk settings such as hospitalization for medical illness and the postsurgical period. Emerging new data from randomized studies have focused on outpatient prophylaxis, suggesting potential benefits in this setting as well. Treatment of cancer‐associated thrombosis requires long‐term anticoagulation with LMWH. Results from ongoing and planned trials of novel anticoagulants in the cancer setting are awaited. Am. J. Hematol. 2012.Keywords
This publication has 64 references indexed in Scilit:
- Venous thromboembolism and prognosis in cancerThrombosis Research, 2010
- Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in MalignancyClinical Cancer Research, 2009
- Role of Tissue Factor in CancerJournal of Clinical Oncology, 2009
- Assessing Risk of Venous Thromboembolism in the Patient With CancerJournal of Clinical Oncology, 2009
- Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The ‘GISCAD-alternating schedule’ study findingsEuropean Journal of Cancer, 2009
- Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancerJournal of Thrombosis and Haemostasis, 2008
- Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic reviewJournal of Experimental & Clinical Cancer Research, 2008
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patientsThrombosis Research, 2008
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999